专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2341923A2 PHARMACEUTICAL COMPOSITION COMPRISING COENZYME Q10 审中-公开
标题翻译：与辅酶Q10的药物组合物
公开(公告)号：EP2341923A2
公开(公告)日：2011-07-13
申请号：EP09817367.7
申请日：2009-09-25
申请人： Sharma, Saumya , Thakur, Srinath , Setty, Swati , Kulkarni, Rajesh , Kulkarni, Shirishkumar
发明人： Sharma, Saumya , Thakur, Srinath , Setty, Swati , Kulkarni, Rajesh , Kulkarni, Shirishkumar
IPC分类号： A61K38/43
CPC分类号： A61K8/355 , A61K9/0063 , A61K31/122 , A61Q11/00
摘要： A pharmaceutical composition for administration in gum pockets caused by periodontal disease, consisting: coenzyme Q10 and pharmaceutically acceptable excipients selected from the group comprising solubilizer; biodegradable polymer; solvent, and/or combinations thereof. A process for making a pharmaceutical composition for administration in pockets in gums caused by periodontal disease, consisting: coenzyme Q10 and pharmaceutically acceptable excipients wherein the solubilizer was dissolved in the solvent with stirring to obtain a clear solution followed by addition of the biodegradable polymer to this solution with stirring to obtain a clear solution; to this solution CoQ10 was added with vortexing to form a uniform suspension.

2. 发明申请

WO2011124953A3 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF TAPENTADOL 审中-公开
标题翻译：对照释放TAPENTADOL的药物组合物
公开(公告)号：WO2011124953A3
公开(公告)日：2012-04-12
申请号：PCT/IB2011000196
申请日：2011-02-07
申请人： LUPIN LTD , DESHMUKH ASHISH ASHOKRAO , BHUTADA PRAVIN MEGHRAJJI , CHANDRAN SAJEEV , KULKARNI SHIRISHKUMAR
发明人： DESHMUKH ASHISH ASHOKRAO , BHUTADA PRAVIN MEGHRAJJI , CHANDRAN SAJEEV , KULKARNI SHIRISHKUMAR
IPC分类号： A61K9/20 , A61K9/16 , A61K9/50 , A61K31/137 , A61K45/06
CPC分类号： A61K9/209 , A61K9/0004 , A61K9/0065 , A61K9/1617 , A61K9/1635 , A61K9/1652 , A61K9/1676 , A61K9/2054 , A61K9/2077 , A61K9/5026 , A61K9/5042 , A61K31/137 , A61K45/06 , A61K2300/00
摘要： A once daily controlled release pharmaceutical compositions comprising tapentadol, wherein preferably the mean Tmax of tapentadol is reached after 10 hours of administration of the composition. The composition comprises tapentadol, such that it maintains serum concentration of tapentadol of at least about 20 ng/ml for at least about 17 hours after oral administration of the composition. According to one embodiment the controlled release pharmaceutical composition comprises tapentadol, which is gastroretentive.
摘要翻译：包含他喷他多的一次每日控释药物组合物，其中优选在施用组合物10小时后达到他喷他多的平均Tmax。组合物包含他喷他多，使得其在口服给药组合物后至少约17小时维持至少约20ng / ml的他喷他多的血清浓度。根据一个实施方案，控释药物组合物包含胃酸滞留的他喷他多。

3. 发明申请

WO2011101734A2 TASTE-MASKED POWDER FOR SUSPENSION COMPOSITIONS OF METHYLPREDNISOLONE 审中-公开
标题翻译：用于甲基泼尼松龙悬浮组合物的吸收粉末
公开(公告)号：WO2011101734A2
公开(公告)日：2011-08-25
申请号：PCT/IB2011/000341
申请日：2011-02-22
申请人： LUPIN LIMITED , BHUTADA, Pravin, Meghrajji , DESHMUKH, Ashish, Ashokrao , GORE, Prakash, Bhagwat , BADHE, Umesh, Ganesh , CHANDRAN, Sajeev , KULKARNI, Shirishkumar
发明人： BHUTADA, Pravin, Meghrajji , DESHMUKH, Ashish, Ashokrao , GORE, Prakash, Bhagwat , BADHE, Umesh, Ganesh , CHANDRAN, Sajeev , KULKARNI, Shirishkumar
IPC分类号： A61K9/14
CPC分类号： A61K9/14 , A61K9/0095 , A61K9/146 , A61K9/1617 , A61K9/1623 , A61K9/1641 , A61K9/1652 , A61K9/5026 , A61K9/5078 , A61K31/573 , A61K47/585 , A61K47/6951 , B82Y5/00
摘要： A dry taste masked powder composition comprising a steroid or its salts or derivatives and pharmaceutically acceptable excipients. The taste-masked powder may be used for suspension compositions suitable for use as a liquid suspension for children and elderly patients.
摘要翻译：包含类固醇或其盐或衍生物和药学上可接受的赋形剂的干味掩蔽粉末组合物。掩味粉末可用于适合用作儿童和老年患者的液体悬浮液的悬浮组合物。

4. 发明申请

WO2010038239A2 PHARMACEUTICAL COMPOSITION COMPRISING COENZYME Q10 审中-公开
标题翻译：包含酵素的药物组合物Q10
公开(公告)号：WO2010038239A2
公开(公告)日：2010-04-08
申请号：PCT/IN2009000525
申请日：2009-09-25
申请人： SHARMA SAUMYA , THAKUR SRINATH , SETTY SWATI , KULKARNI RAJESH , KULKARNI SHIRISHKUMAR
发明人： SHARMA SAUMYA , THAKUR SRINATH , SETTY SWATI , KULKARNI RAJESH , KULKARNI SHIRISHKUMAR
IPC分类号： A61K8/35
CPC分类号： A61K8/355 , A61K9/0063 , A61K31/122 , A61Q11/00
摘要： A pharmaceutical composition for administration in gum pockets caused by periodontal disease, consisting: coenzyme Q10 and pharmaceutically acceptable excipients selected from the group comprising solubilizer; biodegradable polymer; solvent, and/or combinations thereof. A process for making a pharmaceutical composition for administration in pockets in gums caused by periodontal disease, consisting: coenzyme Q10 and pharmaceutically acceptable excipients wherein the solubilizer was dissolved in the solvent with stirring to obtain a clear solution followed by addition of the biodegradable polymer to this solution with stirring to obtain a clear solution; to this solution CoQ10 was added with vortexing to form a uniform suspension.
摘要翻译：一种由牙周病引起的口香糖口服药物组合物，包括：辅酶Q10和药学上可接受的赋形剂，选自增溶剂; 可生物降解聚合物; 溶剂和/或其组合。制备牙周疾病引起的牙龈袋中给药的药物组合物的方法，其包括：辅酶Q10和药学上可接受的赋形剂，其中在搅拌下将增溶剂溶解在溶剂中以获得澄清溶液，随后向其中加入生物可降解聚合物溶液搅拌以获得澄清溶液; 向该溶液中添加CoQ10以涡旋形成均匀的悬浮液。

5. 发明申请

WO2009008006A2 PHARMACEUTICAL COMPOSITIONS FOR GASTROINTESTINAL DRUG DELIVERY 审中-公开
标题翻译：用于胃肠道给药的药物组合物
公开(公告)号：WO2009008006A2
公开(公告)日：2009-01-15
申请号：PCT/IN2008/000401
申请日：2008-06-24
申请人： LUPIN LIMITED , JAHAGIRDAR, Harshal, Anil , KULKARNI, Rajesh , KULKARNI, Shirishkumar
发明人： JAHAGIRDAR, Harshal, Anil , KULKARNI, Rajesh , KULKARNI, Shirishkumar
IPC分类号： A61K9/16 , A61K9/20
CPC分类号： A61K47/44 , A61K9/0065 , A61K9/0095 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/205 , A61K9/2054 , A61K9/2086 , A61K9/209 , A61K31/196 , A61K31/197 , A61K31/437 , A61K31/4402 , A61K31/606 , A61K31/635 , A61K31/655 , A61K31/785 , A61K38/12 , A61K47/32 , A61K47/34 , A61K47/38
摘要： A novel pharmaceutical composition, which comprises a therapeutically effective amount of active principle(s) or a pharmaceutically acceptable salt or enantiomer or polymorph thereof, optionally one or more release controlling agent(s) and pharmaceutical acceptable excipient(s) thereof, wherein the composition is formulated to increase the residence time of the said pharmaceutical composition and/or active principle(s) in the gastrointestinal tract. A novel pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is controlled release. A pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/ fast release and the other is bioadhesive. A pharmaceutical composition comprising: at least two entities wherein one entity is controlled release and the other is bioadhesive All the three compositions are formulated to increase the residence time of active principle(s) in the gastrointestinal tract. A multilayered composition with active in a layer which provides immediate release or controlled release of active principles and layer providing increased residence time in the GI tract.
摘要翻译：一种新型药物组合物，其包含治疗有效量的活性成分或其药学上可接受的盐或对映体或多晶型物，任选的一种或多种释放控制剂及其药学上可接受的赋形剂，其中所述组合物配制成增加所述药物组合物和/或活性成分在胃肠道中的停留时间。一种新型药物组合物，其包含至少两个实体，其中一个实体是即时释放/快速释放，另一个实体是控制释放的。包含至少两个实体的药物组合物，其中一个实体是立即释放/快速释放，另一个是生物粘附的。一种药物组合物，其包含：至少两个实体，其中一个实体被控制释放，另一个实体是生物粘附剂。所有三种组合物被配制以增加活性成分在胃肠道中的停留时间。在层中具有活性的多层组合物，其提供活性成分和层的即时释放或控制释放，从而在GI道中提供增加的停留时间。

6. 发明申请

WO2009008005A1 PHARMACEUTICAL COMPOSITIONS OF RIFAXIMIN 审中-公开
标题翻译： RIFAXIMIN的药物组合物
公开(公告)号：WO2009008005A1
公开(公告)日：2009-01-15
申请号：PCT/IN2008/000397
申请日：2008-06-23
申请人： LUPIN LIMITED , JAHAGIRDAR, Harshal, Anil , KULKARNI, Rajesh , KULKARNI, Shirishkumar
发明人： JAHAGIRDAR, Harshal, Anil , KULKARNI, Rajesh , KULKARNI, Shirishkumar
IPC分类号： A61K9/20 , A61K31/44
CPC分类号： A61K31/44 , A61K9/1623 , A61K9/1652 , A61K9/2086 , A61K9/2846 , A61K9/2866 , A61K9/4808 , Y02A50/473 , Y02A50/475
摘要： A pharmaceutical composition comprising therapeutically effective amount of rifaximin or pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s) and release controlling agent(s). Pharmaceutical composition of rifaximin comprising: at least two entities wherein one entity is an immediate release or fast release and the other is controlled release. The pharmaceutical composition in the form of multilayer tablet comprising, at least one layer comprising, therapeutically effective amount of rifaximin or pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s); said layer providing controlled release rifaximin; and at least one layer which provides increased residence time of the dosage form in the gastrointestinal tract. The pharmaceutical formulation comprising rifaximin having an in vitro dissolution profile, wherein about 70% of rifaximin is released in about 24 hours. The composition comprising therapeutically effective amount of rifaximin or pharmaceutically acceptable salt(s) or enantiomer(s) or polymorph(s) thereof, one or more release controlling agent(s) and pharmaceutically acceptable excipient(s) causing pathogenic eradication.
摘要翻译：一种药物组合物，其包含治疗有效量的利福昔明或其药学上可接受的盐或对映异构体或其多晶型物，药学上可接受的赋形剂和释放控制剂。利福昔明的药物组合物包括：至少两个实体，其中一个实体是立即释放或快速释放，另一个实体是控制释放的。多层片剂形式的药物组合物，包含至少一层，其包含治疗有效量的利福昔明或其药学上可接受的盐或对映体或其多晶型物，药学上可接受的赋形剂; 所述层提供受控释放的利福昔明; 以及提供剂型在胃肠道中的延长停留时间的至少一个层。包含具有体外溶出曲线的利福昔明的药物制剂，其中约70％的利福昔明在约24小时内释放。所述组合物包含治疗有效量的利福昔明或其药学上可接受的盐或对映异构体或多晶型物，一种或多种释放控制剂和引起致病根除的药学上可接受的赋形剂。

7. 发明申请

WO2012110912A1 SUSTAINED RELEASE COMPOSITION OF MEMANTINE 审中-公开
标题翻译：持续发布记忆组成
公开(公告)号：WO2012110912A1
公开(公告)日：2012-08-23
申请号：PCT/IB2012/050539
申请日：2012-02-07
申请人： LUPIN LIMITED , BHUTADA, Pravin, Meghrajji , DESHMUKH, Ashish, Ashokrao , CHANDRAN, Sajeev , RAGHAVAN, Vineeth , KULKARNI, Shirishkumar
发明人： BHUTADA, Pravin, Meghrajji , DESHMUKH, Ashish, Ashokrao , CHANDRAN, Sajeev , RAGHAVAN, Vineeth , KULKARNI, Shirishkumar
IPC分类号： A61K9/16 , A61K9/50 , A61K31/13
CPC分类号： A61K9/5073 , A61K9/1676 , A61K9/5047 , A61K9/5078 , A61K31/13
摘要： The present invention is a sustained release pharmaceutical composition comprising; a core comprising memantine or its pharmaceutically acceptable salts and one or more pharmaceutical acceptable excipient(s), and a sustained release coating comprising the water insoluble substance and a water soluble substance wherein ratio of the water insoluble substance to the water soluble substance is from about 1:0 to about 3.5:1, optionally containing an immediate release coating comprising memantine over the sustained release coating.
摘要翻译：本发明是一种缓释药物组合物，其包含：包括美金刚或其药学上可接受的盐和一种或多种药学上可接受的赋形剂的核心，以及包含水不溶性物质和水溶性物质的缓释包衣，其中水不溶性物质与水溶性物质的比例为约 1：0至约3.5：1，任选地包含在缓释涂层上包含美金刚的速释涂层。

8. 发明申请

WO2012020301A3 ORAL CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF BLONANSERIN 审中-公开
标题翻译：口香糖的口服控制释放药物组合物
公开(公告)号：WO2012020301A3
公开(公告)日：2012-04-26
申请号：PCT/IB2011001843
申请日：2011-08-10
申请人： LUPIN LTD , BHUTADA PRAVIN MEGHRAJJI , DESHMUKH ASHISH ASHOKRAO , CHANDRAN SAJEEV , KULKARNI SHIRISHKUMAR
发明人： BHUTADA PRAVIN MEGHRAJJI , DESHMUKH ASHISH ASHOKRAO , CHANDRAN SAJEEV , KULKARNI SHIRISHKUMAR
IPC分类号： A61K9/20 , A61K9/28 , A61K9/48 , A61K31/519 , A61K49/00
CPC分类号： A61K31/496 , A61K9/2054 , A61K9/2072 , A61K9/2077 , A61K9/2081 , A61K9/209 , A61K9/2846 , A61K9/2853 , A61K9/2866 , A61K9/4866 , A61K9/5026 , A61K9/5078 , A61K31/519
摘要： An oral controlled release pharmaceutical composition comprising Blonanserin and release controlling agent(s) and optionally pharmaceutically acceptable excipients is provided. The present invention further relates to a controlled release pharmaceutical composition comprising Blonanserin and release controlling agent(s) such that the composition releases not less than about 80% of Blonanserin within 20 hours, when dissolution is carried out in 900 ml, 0.1 N HCI, USP apparatus Type II (Paddle) at 50 rpm for 20 hrs. The controlled release pharmaceutical composition of the invention releases 50% of Blonanserin between about 4 to 14 hours, when dissolution is carried out in 900 ml, 0.1 N HCI, USP apparatus Type II (Paddle) at 50 rpm.
摘要翻译：提供了包含布南色林和释放控制剂和任选药学上可接受的赋形剂的口服控释药物组合物。本发明进一步涉及包含布南色林和释放控制剂的控释药物组合物，使得当在900ml，0.1N HCl中进行溶解时，组合物在20小时内释放不少于约80％的布南色林， USP设备II型（桨）以50rpm的转速搅拌20小时。当在900ml，0.1N HCl，II型USP装置（桨式）中以50rpm进行溶解时，本发明的控释药物组合物释放50％的布南色林约4至14小时。

9. 发明申请

WO2012028922A3 CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF MILNACIPRAN 审中-公开
公开(公告)号：WO2012028922A3
公开(公告)日：2012-03-08
申请号：PCT/IB2011/001955
申请日：2011-08-26
申请人： LUPIN LIMITED , KULKARNI, Shirishkumar , KULKARNA, Rajesh , JADHAV, Pandharinath , TIWARI, Ashish
发明人： KULKARNI, Shirishkumar , KULKARNA, Rajesh , JADHAV, Pandharinath , TIWARI, Ashish
IPC分类号： A61K31/165 , A61K9/20 , A61K9/28
摘要： A controlled release pharmaceutical compositions comprising Milnacipran or pharmaceutically acceptable salts thereof is provided. The pharmaceutical composition comprises an immediate release core comprising Milnacipran or pharmaceutically acceptable salts thereof, pharmaceutically acceptable excipients and a coating on the immediate release core comprising rate controlling agents.

10. 发明申请

WO2010010568A1 ORAL COMPOSITIONS OF CLINDAMYCIN 审中-公开
标题翻译： CLINDAMYCIN口服组合物
公开(公告)号：WO2010010568A1
公开(公告)日：2010-01-28
申请号：PCT/IN2008/000579
申请日：2008-09-10
申请人： LUPIN LIMITED , WALZADE, Kalpana , KULKARNI, Rajesh , KULKARNI, Shirishkumar
发明人： WALZADE, Kalpana , KULKARNI, Rajesh , KULKARNI, Shirishkumar
IPC分类号： A61K9/00
CPC分类号： A61K9/0095 , A61K9/1623 , A61K9/1641 , A61K9/5026 , Y02A50/411
摘要： A taste masked pharmaceutical composition of clindamycin, or a pharmaceutically acceptable salt(s), hydrate(s), solvate(s) and physiologically functional derivative(s) and precursors thereof, which includes all polymorphic forms, whether crystalline or amorphous comprising polyhydric alcohol(s); and one or more other pharmaceutically acceptable excipient(s). A process for preparation of a taste masked pharmaceutical composition of clindamycin or a pharmaceutically acceptable salt(s) thereof the said process comprising the steps of a) dry mixing clindamycin, polyhydric alcohol and other pharmaceutically acceptable excipient(s) to get a dry mixture; b) granulating the dry mixture above with a granulating liquid prepared by mixing the suitable pharmaceutically acceptable excipient(s) with aqueous /non-aqueous fluid to obtain a wet mass; c) drying the wet mass to obtain the discrete particles; d) lubricating the discrete particles obtained with a suitable lubricating agent and/or flavour(s).
摘要翻译：克林霉素或其药学上可接受的盐，水合物，溶剂合物和生理功能衍生物及其前体的掩味药物组合物，其包括所有多晶型物，无论是多晶型还是含有多元醇的无定形物质（一个或多个）; 和一种或多种其它药学上可接受的赋形剂。制备克林霉素或其药学上可接受的盐的掩味药物组合物的方法，所述方法包括以下步骤：a）将克林霉素，多元醇和其它药学上可接受的赋形剂干混以得到干混合物; b）将上述干混合物用通过将合适的药学上可接受的赋形剂与水/非水性流体混合而制备的造粒液体制粒得到湿物质; c）干燥湿物质以获得离散颗粒; d）润滑用合适的润滑剂和/或风味获得的离散颗粒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式